Blood Res.  2014 Dec;49(4):279-280. 10.5045/br.2014.49.4.279.

Tumor flare reaction in a patient with mantle cell lymphoma

• Kayar Y
• Bayram Kayar N

• KMID: 2270688
• DOI: http://doi.org/10.5045/br.2014.49.4.279

Abstract

No abstract available.

MeSH Terms

Humans
Lymphoma, Mantle-Cell*

Figure

• 

  Fig. 1 The patient's throat magnetic resonance imaging scan showing a heterogeneously dense mass, sized approximately 65×29 mm at its broadest point, with its borders not clearly identified; therefore, the mass caused distinct asymmetry in the hypopharynx and oropharynx, displaced the uvula to the right side, and continued to the epiglottis level.

Reference

1. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008; 26:2519–2525. PMID: 18427150.

2. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006; 24:5343–5349. PMID: 17088571.

3. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008; 111:5291–5297. PMID: 18334676.

4. Corazzelli G, De Filippi R, Capobianco G, et al. Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol. 2010; 85:87–90. PMID: 20029955.

5. Eve HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol. 2010; 151:410–412. PMID: 20880113.